Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results
Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 SOLANA BEACH, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial
View HTML
Toggle Summary Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™
SOLANA BEACH, Calif. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the
View HTML
Toggle Summary Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™
EVERSANA to commercialize and distribute Gimoti in the U.S. EVERSANA to provide $5 million revolving credit facility upon FDA approval SOLANA BEACH, Calif. and CHICAGO , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
View HTML
Toggle Summary FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™
PDUFA Target Goal Date is June 19, 2020 SOLANA BEACH, Calif. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S.
View HTML
Toggle Summary Evoke Resubmits Gimoti™ New Drug Application to FDA
SOLANA BEACH, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S.
View HTML
Toggle Summary Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement
SOLANA BEACH, Calif. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 29, 2019 , it received notification from the Listing Qualifications Department of
View HTML
Toggle Summary Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price
SOLANA BEACH, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019 , it received notification from the Listing Qualifications Department of
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2019 Financial Results
Gimoti NDA resubmission on track for fourth quarter 2019 SOLANA BEACH, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third
View HTML
Toggle Summary Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™
SOLANA BEACH, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti
View HTML
Toggle Summary Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results
NDA resubmission anticipated in fourth quarter 2019 SOLANA BEACH, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that following receipt of U.S.
View HTML